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ABSTRACT Sequence-specific DNA-binding small mole-
cules that can permeate human cells potentially could regulate
transcription of specific genes. Multiple cellular DNA-binding
transcription factors are required by HIV type 1 for RNA
synthesis. Two pyrrole–imidazole polyamides were designed
to bind DNA sequences immediately adjacent to binding sites
for the transcription factors Ets-1, lymphoid-enhancer bind-
ing factor 1, and TATA-box binding protein. These synthetic
ligands specifically inhibit DNA-binding of each transcription
factor and HIV type 1 transcription in cell-free assays. When
used in combination, the polyamides inhibit virus replication
by >99% in isolated human peripheral blood lymphocytes,
with no detectable cell toxicity. The ability of small molecules
to target predetermined DNA sequences located within RNA
polymerase II promoters suggests a general approach for
regulation of gene expression, as well as a mechanism for the
inhibition of viral replication.
Simple rules have been developed to rationally control the
sequence specificity of minor-groove binding polyamides con-
taining pyrrole (Py) and imidazole (Im) amino acids (1–6).
DNA recognition depends on a code of side-by-side aromatic
amino acid pairings in the minor groove. A pyrrole opposite an
imidazole (PyyIm pairing) targets a CzG bp whereas ImyPy
targets a GzC bp. A PyyPy pair binds both AzT and TzA pairs.
These compounds represent the only class of synthetic small
molecules that can bind predetermined DNA sequences with
affinities and specificities comparable to DNA-binding pro-
teins (7). The DNA-binding activity of the 5S RNA gene-
specific transcription factor TFIIIA was inhibited by an eight-
ring hairpin polyamide that bound within the recognition site
of zinc finger four in the DNA minor groove. As a result,
transcription of 5S RNA genes by RNA polymerase III was
suppressed in vitro and in cultured Xenopus cells (8). The
question arises whether polyamides can permeate human cells
and specifically regulate genes transcribed by pol II (RNA
polymerase II). As a first case study, we examined the ability
of polyamides to inhibit HIV type 1 (HIV-1) transcription in
cell-free assays and viral replication in human lymphocytes.
The HIV-1 enhancerypromoter element contains binding
sites for the cell-encoded proteins upstream stimulatory factor,
Ets-1, lymphoid-enhancer binding factor 1 (LEF-1) the nuclear
factors NF-kB, Sp1, and TATA-box binding protein (TBP)
(Fig. 1 A) (9). To shut-down the promoter, polyamides were
designed to target the transcription factors TBP, LEF-1, and
Ets-1 simultaneously. TBP is indispensable for initiation of
HIV-1 transcription, and LEF-1, considered to be an archi-
tectural protein, plays a central role in coordinating activities
of multiple transcription factors (10). Both TBP and LEF-1
bind the minor groove of DNA and are likely to be inhibited
by the minor groove binding polyamides. Ets-1 predominantly
contacts the major groove in the center of its binding site, with
additional f lanking contacts that are possibly in the minor
groove (11, 12).
The DNA-recognition sites of these transcription factors are
not optimal polyamide target sequences because they are
found in the promoters of many cellular protein-coding genes.
However, the sequences immediately flanking these transcrip-
tion factor binding sites often are conserved for a particular
gene, providing an address for gene-specific targeting. This
study demonstrates how gene-specific polyamide inhibition
can be achieved by targeting sequences that are located
adjacent to, but do not coincide with, binding sites for tran-
scriptional regulators and how strategic targeting of multiple
transcription factors can result in effective inhibition of a pol
II promoter and viral replication in human cells.
METHODS
Polyamides. Polyamides 1–4 were synthesized by solid phase
methods as described (13).
DNA-Binding Assays. Recombinant human TBP (Promega)
was used at 0.14 nM in gel mobility shift experiments with 100
ng of poly dG-poly dC per 10 ml of reaction as recommended.
A 50-bp kinase-labeled oligonucleotide, corresponding to po-
sitions 246 to 14 of the HIV-1 promoter (9), was used at 1.5
nM final concentration. The adenovirus major late promoter
TATA region oligonucleotide had the top-strand sequence
59-GATCGGGGGCTATAAAAGGGGGTGGG-39 and the
complementary bottom-strand sequence. Six percent nonde-
naturing polyacrylamide gels containing 44 mM Tris-borate
(pH 8.3), 1 mM EDTA, 4 mM MgCl2, and 0.02% (volyvol)
Nonidet P-40 were used. Recombinant LEF-1 protein con-
taining the 86-aa DNA-binding domain was the generous gift
of J. Love (Scripps Research Institute, La Jolla, CA) (14).
DNA binding reactions, containing 8 nM LEF-1, were per-
formed in 10 mM Hepes-OH (pH 7.5), 100 mM KCl, 1 mM
DTT, 1 mM MgCl2, 10% (volyvol) glycerol, 250 ng of poly
dG-poly dC, and 50 pmol of a singly end-labeled 400-bp
restriction fragment isolated from pHIV long terminal repeat–
chloramphenicol acetyl transferase plasmid DNA (obtained
from K. A. Jones, Salk Institute, La Jolla, CA) (15). DNase I
footprinting reactions were as described (7). Recombinant
Ets-1 DNA binding domain (DN331) kindly was provided by B.
Graves, (University of Utah) and was used at 12 nM in gel
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mobility shift experiments (16) along with 50 pmol of a 43-bp
HIV-1 oligonucleotide (positions 2160 to 2117).
In Vitro Transcription. Transcription was monitored with a
nuclear extract from HeLa cells (Promega). The human lym-
phoid cell line H9 (ATCC HTB 176) was grown as described
(17), and whole-cell extracts were prepared by hypotonic lysis
(18). Run-off RNA transcripts of '300 bases [cytomegalovirus
(CMV) major immediate early promoter linked to a guanine-
less cassette, pE1B-GL (19)] and '500 bases (pHIV long
terminal repeat–chloramphenicol aceytyl transferase) were
obtained with EcoRI-digested plasmid DNA (100 ng per 25 ml
reaction). Polyamide-DNA complexes were allowed to form at
ambient temperature for 15–30 min before addition of extracts.
Transcription reactions were carried out as described (17). The
H9 cell extract was immunodepleted with antibody to LEF-1
(provided by K. Jones) prebound to protein A Sepharose beads
as described (17). The efficiency of immunodepletion was
determined by subjecting depleted and mock-depleted extracts
to SDSyPAGE and Western blotting and was found to be
.95%. The blot was probed with LEF-1 antibody (diluted
1:2500) and was detected by enhanced chemiluminescence
(Amersham).
Virus Replication. Human peripheral blood mononuclear
cells (PBMC) were separated from whole blood collected from
normal adult volunteers by density gradient centrifugation as
described (20, 21). Donors were provided by the General
Clinical Research Center of The Scripps Research Institute,
which is supported by National Institutes of Health Grant MO1
RR00833. PBMC were activated with 2 mgyml phytohemag-
glutinin and 20 unitsyml of interleukin 2 for 2–3 days before
HIV-1 infection. Each culture of 5 3 105 PBMC was infected
with 103 tissue culture infectious doses of HIV-1 for 24 hours;
free virus was removed by washing the cells in medium, and
polyamides were added to the culture. Virus replication in
culture was measured by HIV-1 p24 viral capsid antigen
ELISA (Dupont). Assays of HIV-1 replication were per-
formed five times with five human PBMC donors.
RESULTS AND DISCUSSION
Polyamide Design. The sequence 59-(A,T)GC(A,T)GC(A,
T)-39 is present on both sides of the TATA box and immedi-
ately upstream of the Ets-1 binding site. The sequence 59-
AGTACT-39 is found between the recognition sites for Ets-1
and LEF-1 (Fig. 1A). These sequences are conserved for most
reported strains of HIV-1 (22, 23). Although the propensity for
mutation at these sites is unknown, allowed sequence changes
in the promoter could be targeted with new polyamides
designed by the pairing rules. According to these rules, 59-
(A,T)GC(A,T)GC(A,T)-39 sequences may be targeted by hair-
pin polyamide 1 having sequence composition ImPy-b-ImPy-
g-ImPy-b-ImPy-b-Dp (Fig. 1B). Because the byb pairing rec-
ognizes both AzT and TzA bp (24), polyamide 1 is expected to
bind to all three sites. Quantitative footprint titration exper-
iments revealed that polyamide 1 binds to each of these sites
with an equilibrium dissociation constant (Kd) of 0.05 nM. A
mismatch control polyamide ImIm-b-ImIm-g-PyPy-b-PyPy-
b-Dp (2), which differs only in the placement of the Im and Py
amino acids, binds the 59-(A, T)GC(A, T)GC(A, T)-39 sites
with 100-fold reduced affinity relative to polyamide 1. Ac-
cording to the pairing rules, the sequence 59-AGTACT-39,
between the LEF-1 and Ets-1 binding sites, will be bound by
polyamide 3 of sequence composition ImPyPyPy-g-ImPyPyPy-
b-Dp (Fig. 1B) (7). Quantitative footprint titration experi-
ments revealed that polyamide 3 binds this site with Kd 5 0.06
nM. Mismatch polyamide 4 binds this sequence with .100-fold
reduced affinity.
Inhibition of TBP Binding. Binding of the TBP subunit of
TFIID in the minor groove nucleates assembly of the pol II
transcription machinery for TATA-containing genes (25–27).
TBP binds the HIV-1 TATA element with a Kd of '1–3 nM.
A gel mobility shift assay revealed that polyamide 1 inhibits
TBP binding to a double stranded oligonucleotide correspond-
ing to the HIV-1 TATA box region (Fig. 2 A, lanes 3–5)
whereas no inhibition was observed for control polyamide 2
(Fig. 2A, lanes 13–15). Additionally, polyamide 1 does not
inhibit TBP binding to the TATA box region of the adenovirus
major late promoter (59-GGGGGCTATAAAAGGGGGT-
39), which contains mismatch flanking sequences (Fig. 2 A,
lanes 8–10). The half-life of the polyamide 1-DNA complex
was determined by competition experiments to be in excess of
2.5 hours.
Inhibition of Ets-1 Binding. The Ets-1 recognition site in the
HIV-1 enhancer is f lanked by binding sites for polyamides 1
and 3 (Fig. 1). The isolated Ets-1 DNA-binding domain,
DN331 (amino acids 331 to 416) (16) bound to the HIV-1
enhancer with a Kd of '0.5 nM. When polyamides were
preincubated with the labeled, double-stranded HIV-1 oligo-
nucleotide before adding DN331, polyamide 3 had no effect on
Ets-1 DNA-binding (Fig. 2B, lanes 3–5). Polyamide 1, how-
FIG. 1. Polyamide and transcription factor binding sites. (A)
Schematic of the HIV-1 enhancer and promoter (nucleotide positions
2199 to 11) showing binding sites for polyamides 1 and 3 and the
transcription factors upstream stimulatory factor, Ets-1 (39, 40),
LEF-1, NF-kB, Sp1, and TFIID (TBP). For polyamide binding models:
shaded and unshaded circles, Im and Py rings, respectively; curved
lines, g-aminobutyric acid (g); diamonds, b-alanine (b); and Dp,
dimethylaminopropylamide. (B) Structures of polyamides ImPy-b-
ImPy-g-ImPy-b-ImPy-b-Dp (1), ImIm-b-ImIm-g-PyPy-b-PyPy-b-Dp
(2), ImPyPyPy-g-ImPyPyPy-b-Dp (3), and ImPyPyPy-g-PyPyPyPy-
b-Dp (4). Binding models and measured dissociation constants are
shown. Mismatches are highlighted.
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ever, prevented the Ets-1yDNA complex formation (Fig. 2B,
lanes 9–11). The two mismatch polyamides 2 and 4 did not
prevent complex formation (lanes Fig. 2B, lanes 6–8 and
12–14). DNase I footprinting revealed that polyamide 1 pre-
vents Ets-1 DNA-binding whereas polyamide 3 cooccupies the
DNA with Ets-1. Polyamide 1 likely inhibits Ets-1 binding by
steric interaction with protein contacts in the minor groove
whereas polyamide 3, which does not inhibit Ets-1 binding,
must occupy the minor groove beyond the Ets-1 contacts.
Inhibition of LEF-1 Binding. LEF-1 is a member of the high
mobility group family of minor-groove binding proteins (14)
and has been shown to be essential for HIV-1 transcription and
replication in lymphoid cells (28). Three sites on the HIV-1
promoteryenhancer restriction fragment are bound by the
86-aa LEF-1 DNA binding domain, sites L1, L2, and L3 (Fig.
2C), with Kd 5 1.4, 5.8, and 4.9 nM, respectively. The LEF-1
footprint at site L1, characterized by a marked DNase I
hypersensitive site, changes to the polyamide footprint in the
presence of match polyamide 3 (Fig. 2C, lanes 8–14). LEF-1
binding is inhibited 50% at a polyamide 3 concentration of '60
pM. Thus, polyamide 3, located in the minor groove immedi-
ately adjacent to site L1, inhibits LEF-1 binding to this site.
Polyamide 3 inhibits LEF-1 binding to the sites L2 and L3 at
markedly higher polyamide concentrations (3 nM and above;
Fig. 2C, lanes 13–14) because there are no high affinity
polyamide recognition sites adjacent to sites L2 and L3.
Inhibition was observed either by adding the polyamide to the
DNA before LEF-1 or after preincubation of the DNA with
LEF-1, consistent with the relative dissociation constants for
the two binding reactions. Mismatch polyamide 4 failed to
inhibit LEF-1 binding.
Inhibition of Transcription. The effects of polyamides 1 and
2 on HIV-1 transcription were tested in an in vitro transcription
assay with a HeLa cell nuclear extract. Polyamide 1 inhibited
basal transcription from the HIV-1 promoter (Fig. 3A, lanes
2–4) but not from the CMV major immediate early promoter,
which contains a mismatched TATA-flanking sequence (59-
GAGGTCTATATAAGCAGA-39) (Fig. 3A, lanes 6–8). The
mismatch polyamide 2 did not inhibit transcription from either
promoter (Fig. 3A, lanes 10–12 and 14–16). We performed
titrations of polyamide 1 over a wide range of concentrations
(1 to 200 nM) with both of the HIV-1 and CMV templates in
the same reaction. Under these conditions, we observed 50%
inhibition of HIV-1 transcription at 60 nM polyamide 1, which
corresponds to a 6- to 10-fold excess of polyamide over binding
sites (Fig. 3B, closed triangles). No significant inhibition of
CMV transcription was observed (Fig. 3B, open circles).
To test the effects of polyamides 3 and 4 on LEF-1-activated
HIV-1 transcription, we supplemented the HeLa nuclear
extract with a human lymphoid H9 cell extract, which contains
high levels of LEF-1 protein (as determined by Western blot
analysis). The mixture of H9 and HeLa cell extracts stimulated
HIV-1 transcription 2.5- to 3-fold over the level of transcrip-
tion observed with the HeLa extract alone (Fig. 3C, lane 1).
Immunodepletion of LEF-1 protein from the H9 extract
abolished this activated transcription (Fig. 3C, compare lanes
1 and 6). Polyamide 3 inhibited HIV-1 transcription in this
system (Fig. 3C, lanes 2–5) with a 50% reduction of transcrip-
tion observed at 10–30 nM polyamide. Polyamide 3 failed to
inhibit HIV-1 transcription in the LEF-1-depleted extract (Fig.
3C, lanes 7–10). We also monitored the activity of the CMV
major immediate early promoter in both the mock-depleted
and LEF-1-depleted H9 cell extract, with the result that LEF-1
depletion had no effect on CMV transcription. As additional
controls, we tested the effect of the mismatch polyamide 4 on
HIV-1 transcription (Fig. 3D, lanes 4 and 5) and polyamides 3
and 4 on CMV transcription (Fig. 3D, lanes 6–10). No poten-
tial binding sites for either polyamide 3 or 4 are present in the
CMV major immediate early promoter sequence. As expected,
polyamide 3 fails to inhibit CMV transcription (Fig. 3D, lanes
7–8), and polyamide 4 fails to inhibit either HIV-1 or CMV
transcription (Fig. 3D, lanes 4–5 and 9–10).
Notably, polyamide 3 does not inhibit basal transcription,
although binding sites for this polyamide are present at the
start site for transcription and within the HIV-1 RNA coding
sequence (Fig. 2C). These observations suggest that pol II can
transcribe DNA with a polyamide bound in the minor groove
and that polyamides are only inhibitory to transcription when
these compounds interfere with the DNA binding activity of a
required transcription factor.
Inhibition of Virus Replication. Because there are multiple
spliced and unspliced species of HIV-1 RNA with different
FIG. 2. Inhibition of transcription factor binding to the HIV-1
promoter and enhancer. (A) Gel mobility shift assay with TBP and
polyamides 1 and 2. Oligonucleotides corresponding to the HIV-1
TATA box (lanes 1–5 and 11–15) or adenovirus major late promoter
TATA box (lanes 6–10) were incubated with no polyamide (lanes 1, 2,
6, 7, 11, and 12), 50 nM polyamide (lanes 3, 8, and 13), 100 nM
polyamide (lanes 4, 9, and 14), and 200 nM polyamide (lanes 5, 10, and
15) before the addition of recombinant human TBP, as indicated (1).
The positions of free probes (F) and the monomer and dimer
TBP-DNA complexes (B) are indicated. (B) Differential effect of
polyamide 1 and 3 on Ets-1 DNA-binding. Polyamide concentrations
were 100 nM (lanes 3, 6, 9, 12), 200 nM (lanes 4, 7, 10, 13), and 400
nM (lanes 5, 8, 11, 14). (C) DNase I footprint experiment with LEF-1
(lanes 7 to 14) and polyamide 3 used at the following concentrations:
no polyamide (lanes 1 and 7), 10 pM (lanes 2 and 8), 30 pM (lane 9),
0.1 nM (lanes 3 and 10), 0.3 nM (lane 11), 1 nM (lanes 4 and 12), 3
nM (lanes 5 and 13), and 10 nM (lanes 6 and 14). Polyamides and DNA
were incubated before the addition of transcription factors.
12892 Biochemistry: Dickinson et al. Proc. Natl. Acad. Sci. USA 95 (1998)
turn-over kinetics (29), we examined HIV-1 transcription
indirectly by measuring the levels and kinetics of HIV-1
replication in human PBMC in culture. PBMC were infected
with the T cell-tropic HIV-1 strain WEAU1.6 (30, 31) or with
the macrophage-tropic strain SF162 (32, 33). Polyamides were
added to the culture medium, and the levels of HIV-1 p24 viral
capsid protein released into the culture media (primarily as
virions) were determined on subsequent days after infection by
using a standard ELISA assay. In control PBMC cultures with
no added polyamide, viral replication of both strains resulted
in increasing p24 levels between 4 and 10 days of culture (Fig.
5 A and C). Polyamide 1 at 1 mM concentration caused an 80%
reduction in virus whereas polyamide 3 at 1 mM concentration
caused a 60% reduction after 6 to 8 days (Fig. 4A). The
combination of polyamides 1 1 3 inhibited HIV-1 replication
at 10 nM to 1 mM concentration, but the closely related
polyamides 2 1 4 did not (Fig. 4B). The combination of
polyamides 1 and 3 at 1 mM each acted in synergy to reduce
viral p24 levels to below the threshold of detection after 6–8
days for WEAU (,10 pgyml; .99.9% inhibition of viral
replication) (Figs. 4A and 5C) and were as effective as 1 mM
azidothymidine in blocking HIV-1 replication. The macroph-
age-tropic SF162 isolate, which replicates in both macrophages
and CD41 T-lymphocytes, was not inhibited efficiently by
either polyamide alone, but the combination of 1 mM each
polyamide 1 and 3 reduced and eventually blocked its repli-
cation after 10 days (Fig. 5A). Addition of mismatch poly-
amides 2 and 4, which differ by a single atomic substitution (4),
or a rearrangement of the Im and Py amino acids (2), from the
match polyamides, had no effect on the level of virus in the
medium, either alone or in combination (Fig. 4B).
The inhibitory effects of polyamides was not caused by
obvious toxicity. No significant decrease in cell viability was
apparent in PBMC cultures treated with polyamides 1 and 3 for
10 days, in contrast to 90% mortality observed for PBMC cells
treated with 1 mM azidothymidine for the same period (Fig. 5
B and D). Cell viability was slightly higher in WEAU-infected
cultures that were treated with polyamides 1 and 3 than in
untreated cultures (Fig. 5D, filled circles versus open circles),
probably because the cytopathic effect of HIV-1 infection was
reversed completely. Cell recovery was not impacted by poly-
amide treatment but was reduced by azidothymidine treat-
ment.
The observed polyamide inhibition of virus replication is
likely caused by interference with the DNA-binding activities
of TBP and Ets-1 by polyamide 1 and the binding activity of
LEF-1 by polyamide 3, but it is possible that inhibition of
FIG. 3. Polyamide inhibition of HIV-1 transcription in vitro. (A)
DNA templates containing the HIV-1 promoter (lanes 1–4 and 9–12)
and the CMV major immediate early promoter (lanes 5–8 and 13–16)
were incubated with the following concentrations of polyamide 1 or 2
(as indicated) before the addition of HeLa nuclear extract: no poly-
amide (lanes 1, 5, 9, 13) 50 nM polyamide (lanes 2, 6, 10, 14), 100 nM
(lanes 3, 7, 11, 15), and 200 nM (lanes 4, 8, 12, 16). (B) Relative levels
of HIV-1 transcription (closed triangles) compared with CMV tran-
scription (open circles) are plotted as a function of polyamide 1
concentration, from mixed template reactions with HeLa nuclear
extract. (C) Polyamide 3 inhibits LEF-1-activated transcription. Tran-
scription reactions were performed with HeLa nuclear extract sup-
plemented with H9 whole cell extract (lanes 1–5) or LEF-depleted H9
extract (lanes 6–10). The final concentrations of polyamide were no
polyamide (lanes 1 and 6), 10 nM (lanes 2 and 7), 30 nM (lanes 3 and
8), 100 nM (lanes 4 and 9), and 300 nM (lanes 5 and 10). (D)
Transcription with mismatch control polyamide 4 and control CMV
template. Plasmid DNA was incubated with polyamide 3 (10 nM, lanes
2 and 7; 100 nM, lanes 3 and 8) or polyamide 4 (10 nM, lanes 4 and
9; 100 nM, lanes 5 and 10).
FIG. 4. Polyamide inhibition of HIV-1 replication. A and B depict
two independent experiments in which polyamides alone or in com-
bination were added to cultures of PBMCs, obtained from two
separate donors, infected with the primary HIV-1 isolate WEAU 1.6
(kindly provided by G. Shaw). Replication was measured 6 or 8 days
after infection by release of p24 capsid antigen into the medium.
Assays were performed in duplicate and showed ,5% variation from
the mean. In B, polyamides were added 24 hours before virus exposure
and were continuously present thereafter.
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cellular genes involved in T-cell activation could have an
indirect effect on HIV-1 replication. To assess this possibility,
we performed an RNase protection assay for transcripts of a
number of cytokine and growth factor genes, including inter-
leukin 2, interleukin 5, and interleukin 13, which differ in the
target sequences flanking the TATA box. Four other cytokine
genes that lack binding sites for either polyamide 1 or 3 in their
promoters also were examined (Fig. 6). The results show that
exposure of activated human PBMC to a combination of either
polyamides 1 1 3 or 2 1 4 (1 mM each) for 6 days failed to
inhibit RNA expression of all of the genes examined (Fig. 6).
There was no difference in the intensity of CD4 and CD8 RNA
bands (data not shown), indicating equivalent recovery of CD4
and CD8 T cells in treated and untreated cells. This lack of
inhibition of cytokine gene transcription suggests that the
polyamides reduce virus replication in cells by a direct effect
on HIV-1 RNA transcription.
Future Plans. Our present studies show that polyamides
designed to target DNA sequences 6–7 bp in length are
effective inhibitors of gene transcription in cell-free systems
and viral replication in human cells. Because sequences of
these lengths would be highly redundant in the human genome,
it had seemed likely that these ligands would have deleterious
effects on cell metabolism because of interference with the
activity of cellular genes. However, the results described here
indicate that a set of two polyamides that recognize 6- to 7-bp
sequences can be sufficient for gene-specific regulation in vivo.
It is interesting to compare these small molecule transcription
repressors to eukaryotic transcriptional regulatory proteins
that also recognize multiple short sequences to increase func-
tional specificity (27, 34, 35). The observations that polyamides
do not interfere with pol II elongation, and that polyamides
can bind simultaneously with certain major groove proteins,
should further enhance gene-specificity (36). In addition,
polyamides are not limited to 6- to 7-bp recognition. For
example, polyamides of similar size to those described here
have been shown to bind as cooperative dimers to sites 10–16
bp in length (37, 38). The polyamide binding site size required
to elicit optimal biological function should be reported in due
course.
The specific inhibition of genes transcribed by pol II repre-
sents an important first step toward asking whether cell-
permeable small molecule transcription antagonists might
regulate gene expression in complex organisms (8). We have
chosen TBP and two additional key regulators of HIV-1
transcription, Ets-1 and LEF-1, as targets for inhibition of pol
II-driven transcription. Because most tissue-specific cellular
genes and viral genes contain TATA elements as well as
enhancer factor binding sites, this approach may be generally
applicable for the inhibition of most target genes.
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FIG. 5. Kinetics of polyamide inhibition of HIV-1 replication and
effects on cell viability. PBMC were infected with the macrophage-
tropic HIV-1 isolate SF162 (A and B) or the T-cell tropic isolate
WEAU 1.6 (C and D). Polyamides 1 and 3 were added in combination
at 1 mM each. Virus replication was monitored by p24 ELISA (A and
C). Cell viability was determined by trypan blue exclusion in the
presence of polyamides or azidothymidine (B and D).
FIG. 6. Control gene expression. (A) The TATA box (bold) and
flanking sequences (from GenBank listings) of each of the cytokiney
growth factor genes examined are shown. The polyamide 1 binding site
is underlined. (B) Ribonuclease protection assays for the indicated
mRNAs (41, 42). PBMCs were cultured and either were left untreated
or were treated with 10 mM polyamides 1 1 3 or 2 1 4 for six days.
Data are expressed as the intensity of each RNA relative to the
intensity of the ribosomal L32 RNA band to standardize for RNA
loading.
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